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The demand for comprehensive Human Immunodeficiency Virus (HIV) and Acquired 
Immunodeficiency Syndrome (AIDS) services is greater than the available supply, 
particularly for the provision of antiretroviral therapy. The resulting bottleneck in service 
delivery has considerable implications for people living with HIV and for resource 
management.  
Aim 
The purpose of this research was to investigate loss-to-care and associated variables of 
adult HIV-infected people who were eligible for antiretroviral therapy, from July 2004 to 
December 2007 at Sinikithemba HIV Clinic in Durban, KwaZulu-Natal. 
Methods 
An observational descriptive and analytic cohort study design was used. Secondary data 
sourced from Sinikithemba were collated. All HIV-infected adults, 15 years and older 
when registered on the TrakCare database, who were eligible for antiretroviral therapy 
were included in the study. Data were extracted to describe the preparation of HIV-
infected adults who were eligible for antiretroviral therapy. Variables were first 
summarised and described before the confirmatory analytic steps were taken to measure 
associations at the p<0.05 significance level. 
Results 
Of the 10 424 HIV-infected adults registered at Sinikithemba, 5470 (52%) were eligible 
for antiretroviral therapy from July 2004 to December 2007 and 2979 (54%) of these 
were lost to care prior to initiating antiretroviral therapy. Six exposure variables were 
significantly associated with this loss-to-care, (gender, baseline CD4 count, pre-eligibility 
care, antiretroviral therapy delay, preparation step and waiting time). These variables 
remained significantly associated with loss-to-care even after controlling for confounding 
with logistic regression. 
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Discussion and Recommendations 
With the rapid scale-up of antiretroviral therapy programmes, the outcome of those 
people living with HIV lost to care before commencing therapy have not been adequately 
documented. This large cohort enrolled over three-and-a-half years demonstrates that the 
loss-to-care prior to initiation of antiretroviral therapy is a significant problem that needs 
to be further investigated. Focusing retention strategies at the pre-antiretroviral therapy 
stage of HIV care will improve overall programme outcomes. 
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1 CHAPTER I: INTRODUCTION 
“Unless HIV care is available to patients at all stages of HIV infection, the long awaited 
chance to substantially reduce AIDS mortality with ART could fall short of its full 
potential” (1). 
This research report outlines the problem of people living with Human 
Immunodeficiency Virus (PLHIV) lost to care before they are able to initiate 
antiretroviral therapy (ART).  
In chapter 1, the background to the problem and why it was important for this study to 
take place is provided. Chapter 2 contains an outline of the current research on pre-ART 
loss-to-care, whilst in Chapter 3 the methods used to investigate the problem are 
described. 
The final three chapters contain the results of the research, an overview and discussion of 
the relevance and limitations of the research findings in relation to the current literature 
and the conclusions and recommendations based on the research findings. 
1.1 BACKGROUND 
1.1.1 What is known so far? 
The Sinikithemba HIV Clinic, at McCord Hospital has been operational since 1995. At 
that time access to ART was limited and only available through clinical trials or at high 
cost to PLHIV in the private sector.  
In July 2004, Sinikithemba was awarded a grant
1
 to scale up the number of PLHIV 
initiated on ART to 100 per month. When the Department of Health accredited 
Sinikithemba as an ART treatment site in 2007, medication and laboratory testing were 
provided by the provincial Health Department.  
  
                                                 
1
 United States of America,President’s Emergency Fund for AIDS Relief (PEPFAR) 
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The capacity of Sinikithemba to meet the demand for ART was stretched with the rapid 
expansion and large numbers of PLHIV accessing the programme. Donor funding 
previously used for ART medications was redirected to expand ART services through a 
Down Referral Programme with the local eThekwini Municipality. 
In line with the public-private model of health-care provision at McCord Hospital, 
PLHIV attending Sinikithemba are required to contribute a minimal monthly user-fee for 
their care. In the study period July 2004 to December 2007 this fee was Rand 160 per 
month. 
Despite the high numbers of PLHIV who initiate ART at Sinikithemba, many of those 
who enter into care, are lost to care ‘along the way’. Currently the resources available to 
follow up PLHIV lost to care are limited to those who have already initiated ART, due to 
the implications of the development of HIV resistance associated with interruption of 
ART. The policy limited follow-up  means that ART-eligible
2
 PLHIV lost to care prior to 
initiating ART are not actively followed up and reasons for them no longer accessing care 
at Sinikithemba are not known.   
1.1.2 What needs to be known? 
A retrospective chart review conducted at Sinikithemba from July 2006 to December 
2006, showed that 82 (16%) of the 501 ART-eligible PLHIV followed up at that time 
were lost to care before initiating ART. Telephonic follow up of these PLHIV found that 
26 (32%) were deceased (2). 
Understanding the reasons PLHIV do not remain in care is critical to improve patient 
retention and so reduce the associated case fatality. Currently a prospective research 
project underway at McCord Hospital is following up PLHIV from the time they were 
tested for  HIV,  and will investigate the reasons some do not remain in care and 
determine the proportional mortality in this cohort. 
                                                 
2
 Eligibility for ART is determined by a CD4 count  equal to or less than 200 cells/uL 
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However, valuable insights can be gained from retrospectively examining the existing 
data. Considering the length of time Sinikithemba has been operating, a much larger 
sample could be accessed than in the previous retrospective study in order to describe the 
problem in more detail and determine health-system and other factors associated with 
pre-ART
3
 loss-to-care.  
As data are collected and analyzed for this specific stage of HIV care, it will be beneficial 
to compare findings and build on the current understanding of the problem. The research 
will assist health service managers to make informed decisions about HIV service 
delivery and improve the retention of PLHIV in HIV care. 
1.1.3 What is the importance of this study? 
Whilst most published literature focuses on ART programme expansion and patient 
retention, there are only a few sites where researchers have investigated pre-ART attrition 
and associated mortality (2). The high case fatality associated with pre-ART loss-to-care 
shown in these studies makes it imperative that we improve access to HIV care, initiation 
of ART, and expand the scope of care and support offered to PLHIV. 
The reality is that although psychosocial and clinical status should primarily determine 
when and if ART is initiated, waiting lists and limited clinical services for PLHIV due to 
capacity and resource constraints ultimately limit the number who commenced treatment.  
In 2009, the pre-ART services at Sinikithemba were expanded to include primary health 
care (PHC) services in an effort to improve the clinical status of PLHIV prior to ART 
initiation. Yet, without active follow up of pre-ART loss-to-care, it is difficult to 
understand the factors that affect the uptake of these pre-ART services and negate the 
potential gains of this new programme.  
  
                                                 
3
 ART eligible PLHIV who are lost to care prior to initiating ART 
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Understanding the variables, which influence the supply and demand for ART initiation, 
particularly those that can be changed and controlled through the health care system, is 
important to ensure current and new services are effective. 
1.1.4 How will the study solve the problem? 
Operational research, which describes ART preparation and analyzes the variables that 
affect pre-ART loss-to-care, is critical for mobilising resources to expand the uptake of 
HIV services and increase ART initiation. 
1.2 STATEMENT OF THE PROBLEM 
Providing comprehensive HIV care requires health service managers to continually 
expand services and improve quality of medical management as improved therapeutic 
and care modalities become available.  In a resource-limited setting, the challenge lies not 
only in keeping pace with the considerable need for services, but also the manner in 
which service delivery is regulated according to resource availability.  
Due to resource constraints, the demand for comprehensive HIV care is greater than the 
supply, particularly for the provision of ART. The resulting bottleneck in service delivery 
has considerable implications not only for the individual and the overall management of 
the HIV epidemic, but also for resource management. 
The preparation of PLHIV for ART is a resource intensive process and needs to be 
understood better to optimize current service delivery and maximize the benefit of the 
resources invested in the health and preparation of those eligible for ART. 
  
 18
1.2.1 Research Hypotheses 
The main hypothesis for this study is that pre-ART loss-to-care at Sinikithemba HIV 
Clinic is associated with demographic, clinical and health-system variables. These 
variables are specified in the following hypotheses: 
• Pre-ART loss-to-care is associated with age, gender and CD4 count;  
• The proportion of pre-ART loss-to-care for PLHIV varies with the different steps 
involved in the ART preparation process; 
• PLHIV whose care is delayed for psychosocial and clinical reasons during the 
ART preparation process are more likely to be lost to care before initiating ART; 
and  
• The longer the time between steps in the ART preparation process, the more 
likely PLHIV are lost to care before initiating ART. 
1.2.2 Research Question 
What proportion of adult people living with HIV eligible for ART at Sinikithemba HIV 
Clinic were lost to care before initiating ART and what variables are associated with this 
pre-ART loss-to-care? 
1.3 PURPOSE OF THE RESEARCH 
The purpose of this research was to investigate loss-to-care of adult PLHIV who were 
eligible for ART and the associated variables, from July 2004 to December 2007, in order 
to provide information that may improve pre-ART service delivery at Sinikithemba HIV 
Clinic in Durban, KwaZulu-Natal. 
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1.4 SPECIFIC OBJECTIVES OF THE RESEARCH 
The objectives of this study were: 
1. To describe the demographic and clinical characteristics of adult PLHIV in the 
ART preparation process;  
2. To quantify loss-to-care at each stage of ART preparation; 
3. To measure waiting times between each stage of the ART preparation process; 
4. To analyse the association between age, gender, CD4 count and pre-ART loss-to-
care; 
5. To analyse the association between psychosocial and clinical delays and pre-ART 
loss-to-care;  
6. To analyse the association of pre-ART waiting times between steps of the ART 
preparation process and pre-ART loss-to-care;  
7. To investigate any other associations which may arise from analysis of the data; 
and 
8. To make recommendations for improvements for ART preparation at 
Sinikithemba HIV Clinic based on the results of the study. 
 
1.5 ASSUMPTION UNDERLYING THE STUDY 
Every HIV-infected person should have access to HIV care and treatment. However, with 
South Africa having the largest HIV-infected population in the world and limited 
resources for health care, this is not yet the reality (3).  
Understanding the demographic, clinical and health-system factors associated with pre-
ART loss-to-care will assist health service managers to limit the impact of these factors 
on retention of PLHIV in care and ultimately reduce HIV related mortality. 
PLHIV who were ART eligible within the same month, were exposed to the same 
waiting or booking times for ART preparation.  
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1.6 OPERATIONAL DEFINITIONS USED IN THE STUDY 
1.6.1 Adult PLHIV 
PLHIV who entered care at 15-years or older were registered as adults
4
 at the 
Sinikithemba HIV Clinic.  
1.6.2 ART-Eligible  
PLHIV who were eligible to initiate ART had a CD4 count equal to or lower than 200 
cells/uL. In this study, those who were ART eligible were included from the time that a 
CD4 count was available. In the cases where PLHIV had not returned for their CD4 count 
result by the end of the study follow up period, they were counted as ART-eligible and 
lost to care at the same clinic visit.  
1.6.3 ART Preparation 
The clinical and psychosocial services ART-eligible PLHIV receive in preparation for 
ART initiation.  
1.6.4 Baseline CD4 Count 
The first CD4 count equal to or lower than 200 cell/uL was used as a baseline against 
which CD4 count improvement was measured once a PLHIV initiated ART. 
1.6.5 Pre-ART  
PLHIV who were eligible for ART and were undergoing ART preparation. 
1.6.6 Pre-Eligibility Care 
PLHIV who accessed HIV care prior to being eligible for ART and who had routine CD4 
counts tests to monitor their progress to ART eligibility. This positive health-seeking 
                                                 
4
 The Sinikithemba HIV Clinic has a different ART preparation system for children to that of adults, 
therefore this study only included PLHIV who were classified as adults, those 15-years or older. 
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behaviour meant that PLHIV would commence ART as close to the time of becoming 
ART eligible as possible. 
1.6.7 Pre-ART Loss-to-Care 
Pre-ART loss-to-care occurred when a PLHIV was eligible for ART and stopped 
accessing the pre-ART preparation services at the clinic. A PLHIV was defined as being 
lost to care when they had not accessed care for six months or more and the reason for 
not returning to the clinic was unknown. 
1.6.8 Waiting Time 
Waiting time refers to the amount of time, in days, between ART preparation steps.  
1.7 SCOPE OF THE STUDY 
Sinikithemba was the only site included in this study. Information from PLHIV on their 
reasons for leaving ART preparation services was not available. It was not possible to 
ascertain whether PLHIV had transferred care to other services or had died therefore this 
could not be included in the data analysis. 
1.8 CONCLUSION 
Not all eligible PLHIV receive ART and the reasons why are not fully understood. 
Without ART these PLHIV have a significant risk of mortality and there are public health 
implications related to ART-eligible PLHIV not accessing appropriate HIV care and 
treatment. One of the proposed strategies for reducing pre-ART loss-to-care is to expand 
HIV care services.   
However, service-delivery uptake cannot be improved if the factors associated with 
patient retention are not understood. Research that assists health care managers mobilise 
appropriate resources in order to make targeted, effective interventions that improve 
quality of life in PLHIV in resource-limited settings is required.   
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2 CHAPTER II: LITERATURE REVIEW 
INTRODUCTION 
Despite the ability of antiretroviral therapy (ART) to reduce acquired immunodeficiency 
syndrome (AIDS) related mortality, many people living with HIV
5
  (PLHIV) who are 
eligible for ART are still not experiencing its life-saving benefits. With more than 60% of 
HIV-infected people live in sub-Saharan Africa, the mortality associated with failure to 
provide ART to all who need it is considerable and means that there is a far greater 
burden of case fatality than is being see in ART programmes (4,5)  
It is imperative that health system research focuses not only on those PLHIV initiated on 
ART, but also on those who do not ‘make it’. We have to understand the differences 
between those PLHIV who initiate ART and those who do not so that we can better 
manage patient retention and the availability and accessibility of services for all PLHIV 
(4,6,7,8,9). 
2.1 LITERATURE REVIEWED 
2.1.1 Pre-ART Loss-to-Care and mortality 
The Reproductive Health & HIV Research Unit (RHRU) working with the Tshepong 
Wellness Clinic in Klerksdorp, North West province conducted a chart review of all 
patient files in June 2006 to investigate concerns raised about the numbers of PLHIV no 
longer accessing care at the clinic (10). 
A total of 5750 files were reviewed and the files were classified according to specified 
categories, one of which was “Pre-ART Defaulters”. This category consisted of pre-ART 
PLHIV who had visited the Wellness Clinic but had not returned within six weeks of 
their last visit date.   
                                                 
5
 Human Immunodeficiency Virus 
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Of all the PLHIV not initiated on ART, 1765 (73%) were in the “Pre-ART Defaulter” 
category, meaning they were eligible for ART but were no longer still in care (10).  
Nearly half (42%) of those “Pre-ART Defaulters” were found to have died before their 
next scheduled visit (10). This finding is consistent with research at McCord Hospital that 
showed that without ART the median survival time for a PLHIV is less than a year (6).  
In 2005, Lawn et al. analysed a prospective cohort of 712 treatment naïve PLHIV 
accessing a community based ART service to determine the “rates, risk factors and 
causes of death” of PLHIV prior to and following ART initiation. Similarly, they found 
that within 90 days of enrolment into the programme, 29 of 44 (66%) pre-ART PLHIV 
died (4). 
More recently, Fairall et al. conducted a cohort study in the public sector ART project in 
the Free State in which 14 267 PLHIV were followed up for up for 20 months following 
enrolment in the programme. They found that 2105 (87%) of the PLHIV who had died 
had not initiated ART (11). 
This problem is complex in that PLHIV who no longer access care may die, whilst others 
may be lost to care because they accessed care too late and die despite being in care (12).  
The research findings show that even in those PLHIV who have accessed HIV care but 
are eligible for treatment, that a high proportion do not remain in care (4,6,10,11). The 
high mortality found in these studies is one of the main contributors to the high loss-to-




2.1.2 Impact of ART in resource-limited settings 
Due to the considerable resources required to provide comprehensive ART services, 
successful implementation of ART in a resource-limited setting seemed highly 
improbable just a few years ago. The reality of underdeveloped and under-resourced 
health systems, poverty, shortages in skilled health workers and the development of ART 
resistance seemed to overwhelm the potential benefits of introducing ART into these 
settings (13). 
Since then, there has been remarkable expansion in the rollout of ART services in many 
resource-limited settings and the South African National Roll out plan implemented in 
2004 has rapidly increased access to ART (14).  Successful implementation of ART 
programmes and proven strategies and guidelines that are locally appropriate have been 
described, confirming that, “ART can be provided in resource-limited settings with good 
patient retention and clinical outcomes” (15). 
In 2005, Lawn et al. showed in a prospective cohort in Cape Town that the high mortality 
rate of 36 deaths/100 person years found in the pre-ART stage was reduced to 3 deaths 
/100 person years within one year for those who received ART (4). In 2007, Rosen et al. 
conducted a systematic review on patient retention in ART programmes in sub-Saharan 
Africa and found approximately 80% retention of PLHIV after six months on ART and 
60% after two years (6).  
What the expansion of ART services and these figures on mortality and patient retention 
in ART programmes show is that the impact of ART in resource-limited settings is   
dependent on well functioning health systems and the effectiveness of ART programmes 
as much as that of drug efficacy (16). 
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2.1.3 Low ART coverage 
In the World Health Organization "3 by 5 Report on Global Access to ART" (2006), 
developing countries only had 10 to 15% ART coverage. In South Africa ART coverage 
was estimated to be 21% (17).  These figures highlight the number of PLHIV who are 
eligible for ART that do not have access to these services. 
A simulation model of HIV infection in South Africa was used under different scenarios 
of scale-up and expansion of the ART programme to estimate numbers of ART-eligible 
PLHIV and the expected HIV-associated mortality with or without ART. For the current 
time line for ART scale-up in South Africa, the results showed an estimated 1.5 million 
deaths by 2012 (18).  
One of the main reasons for low coverage and high AIDS related mortality projection is 
that most ART systems cannot meet the demand for ART services. Rosen et al. argue that 
ART services will need to be rationed in order to maximize the benefit of ART (7). 
Rationing services creates a difficult ethical situation for individual ART care, but is also 
a public health concern with regards to HIV transmission, prevalence and the issue of 
ART resistance (8,14,19,17). Both HIV and AIDS prevention and treatment programmes 
can influence the HIV and AIDS epidemic; however, they need to be appropriately 
managed to provide services for every HIV-infected person. Any shortfall will continue 
to contribute to the pool of infection fuelling the epidemic. 
2.1.4 Availability and Accessibility of HIV services 
The problem is two-fold in that it is necessary to ensure that PLHIV have equitable 
access to services and commence care at the most appropriate time. Whilst some studies 
have shown very high mortality in PLHIV awaiting ART, delayed access to treatment 
may also account for up to two thirds of early deaths in ART PLHIV (20). 
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There has been a lot of focus on establishing the clinical stage at which PLHIV should 
initiate ART, however more attention needs to be paid to the entire process of ART 
preparation and delivery and its overall efficiency.  To benefit fully from ART, HIV 
positive PLHIV should enter care before they reach advanced stages of immune 
suppression (9).  
Health care access, health system delays and inappropriate treatment criteria are all 
factors that contribute to PLHIV initiating ART too late; these are also some of the 
factors that impact on whether or not PLHIV remain in care before or after ART 
initiation (1,21).  
2.1.5 HIV care retention 
Even if every PLHIV had access to ART exactly when it was required, we still could not 
expect 100% ART coverage. Patient retention has received a lot of attention in ART 
programmes because of the impact attrition has on the outcomes of these programme and 
it would be short sighted to not expect attrition to play a role in HIV care and ART 
preparation.  
In the United States, a study in 2007 on U.S veteran’s showed that even in a system 
where access to HIV services was not limited and PLHIV had very few financial barriers 
to care, retention in HIV and ART care was still a problem (9). Factors that affect the 
uptake of services and patient retention are complex, especially as the health of PLHIV 
changes over time, retention in HIV care has been shown to be a predictor of survival 
with HIV infection (9, 22). 
Whilst it is ultimately an individual’s choice to access care, retention is a good measure 
of programme effectiveness as it is affected by many interrelated factors that involve the 
patient as well as the structure and delivery of services by both the care provider and the 
public health system (22,23,24). Understanding this interplay could provide us with an 
objective way to predict patient retention and adherence risks and ensure PLHIV optimal 
response to ART 
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3 CHAPTER III: METHODS 
3.1 INTRODUCTION 
In the methods section the study design, study setting and study population is outlined.  A 
detailed description of how the data were collected for the study and methods that were 
used to describe and analyse this data are provided as well. A framework for the 
statistical analysis of the data was used, (Table 3.3), to ensure each study objective and 
hypothesis was addressed and that the methods used for the statistical analysis were 
adequately described. 
3.2 STUDY SETTING 
At Sinikithemba HIV Clinic, all people living with HIV (PLHIV) who are eligible for 
antiretroviral therapy (ART) are clinically and psychosocially prepared before ART is 
initiated. ART-eligible PLHIV, 15-years or older, wishing to access ART at Sinikithemba 
have to meet the following ART preparation requirements: 
• Registration on TrakCare, the McCord Hospital Health Management Information 
System (HMIS);  
• Psychosocial assessment addressing patient readiness for ART; 
• Proof of residence within the eThekwini Municipality; 
• Ability to pay the Sinikithemba monthly user-fee; 
• Booked on the ART literacy list; 
• Attendance at all three ART literacy sessions; and 
• Clinically screened and treated for any concurrent opportunistic infections. 
The requirements for accessing ART at Sinikithemba have remained the same since the 
programme commenced in July 2004. Once all of these criteria are met, the PLHIV is 
initiated on ART at the time of the third ART literacy visit, unless clinical or 
psychosocial issues require ART initiation to be delayed. There are six ART preparation 
steps that PLHIV have to follow in order to initiate ART as shown in Figure 3.1. 
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Figure 3.1: Antiretroviral therapy preparation steps for people living with HIV at 
Sinikithemba HIV Clinic, July 2004 to December 2007. 
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3.2.1 The ART preparation process 
People living with HIV could have their HIV and CD4 count results when they enter the 
ART preparation system, or they could have their HIV test and CD4 test done at 
Sinikithemba. If they are not yet eligible for ART, they will be advised to continue to 
have their CD4 count monitored every three or six months, depending on how close their 
CD4 count is to the policy-determined threshold for ART eligibility.  
Returning regularly for follow-up HIV care is considered a demonstration of good health-
seeking behaviour and for the purpose of analysis in this study is classified as ‘pre-
eligibility care’. 
If the CD4 count is equal to or below 200 cells/uL, PLHIV will be referred for a 
psychosocial assessment. Typically, the psychosocial assessment is done on the day they 
return to the clinic to collect their CD4 count result.  
At the psychosocial assessment, ART-eligible PLHIV will be screened by a counsellor to 
assess whether the PLHIV has any psychosocial problems that may affect their ability to 
adhere to their ART medications and clinic visits. Issues dealing with stigma, difficulties 
disclosing to family and friends, or substance abuse problems are addressed with the 
PLHIV and ongoing counselling will be recommended if necessary.  
In some cases, especially for PLHIV with psychological or socioeconomic problems, the 
PLHIV will also be referred to the social workers, psychologists, or both, for further 
assessment and care. Due to ART being life-saving treatment, ART initiation is only 
delayed for psychosocial reasons in extreme cases and in most cases, any unresolved 




The psychosocial counsellors will also assess the ability of PLHIV to pay the monthly 
clinic fee once initiated on ART and secondly whether they are currently residing in the 
Durban Metropolitan Area. These criteria are important indications of the ability of the 
PLHIV to remain in care at Sinikithemba, as they will have to have access to an income 
and be living in close proximity to the clinic to attend monthly clinic visits. If an HIV-
infected person does not meet these criteria the counsellor, and social workers if 
necessary, will assist with a referral to an appropriate HIV clinic. 
Once the psychosocial assessment is completed, the PLHIV will be booked for the first 
ART literacy session. The ART literacy sessions are group sessions facilitated by 
counsellors where stigma, disclosure, lifestyle and behavioural changes, the HIV life-
cycle and ART medications are discussed.  
The ART literacy sessions are scheduled to coincide with the clinical consultations before 
ART is initiated, to screen and treat PLHIV for opportunistic infections. In addition to the 
literacy group sessions and clinical consultation, all those preparing for commencing 
ART have blood samples drawn for routine laboratory testing, and with the high 
prevalence of tuberculosis in KwaZulu-Natal all PLHIV have a chest X-ray taken as well.  
Once all these requirements are met and there are no additional clinical or psychosocial 
problems to deal with, the PLHIV will be initiated on ART. Typically, this will happen at 
the third ART literacy visit. 
3.2.2 ART preparation waiting times 
ART preparation is an intensive process and requires a substantial amount of time and 
resource from both the PLHIV and the health system. Due to limited clinical and 
psychosocial capacity, ART literacy sessions are only offered at scheduled appointment 




In order to maximize the number of PLHIV that can be prepared for ART, the ART 
literacy sessions are scheduled as group sessions. However blood draws, X-rays and 
medical consultations have to be done individually and in order to minimize the number 
of return visits to the clinic for PLHIV, these are all scheduled to coincide with an ART 
literacy session.  
The consequence of grouping these various care activities means that PLHIV can end up 
spending the whole day in the clinic for any one of their ART literacy visits.  The literacy 
sessions typically last one to one-and-a-half hours, whilst a clinical consultation can take 
anything from 20 minutes to assess a healthy, stable patient, to an hour or more if the 
patient is very ill and requires stabilisation, rehydration, minor procedures or further 
investigations.  
As PLHIV are initiated on ART, time has to be scheduled as well for staff to attend to 
those PLHIV on ART returning to the clinic for their monthly clinic visits for monitoring. 
In order to ensure that there is enough staff and clinic space to comfortably and 
confidentially provide services during an eight hour clinic day, the number of ART 
preparation PLHIV booked per ART literacy session has to be limited.  
In addition to this, despite having access to donor funding and Department of Health 
support for medications and laboratory services, the Sinikithemba budget is limited and 
the number of PLHIV being prepared for ART has to be managed to ensure that the 
annual budget is not overspent. These resource constraints result in a limited number of 
ART Literacy session bookings being made available per day.  
3.2.3 ART preparation Batch System 
In 2004, there were only a few sites where ART could be initiated in the province. The 
policy to scale up ART initiation was a new concept to manage and implement rapidly. In 
order to process as many ART-eligible PLHIV as possible in a standardized manner staff 
were required adhere to the new ART guidelines and protocols.  ART preparation was 
implemented using a ‘Batch System’.  
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The Batch System was an ART preparation schedule that worked on a monthly cycle 
taking batches of ART-eligible PLHIV through the ART preparation steps as a group. 
Psychosocial assessments were conducted on an individual basis as PLHIV returned for 
their CD4 count results. From the first ART literacy session, each step was scheduled for 
a specific week of each month. 
In any given month, one week would be dedicated to each of the three ART literacy 
steps, with a one week gap in between the second and third ART literacy sessions. This 
allowed the entire Sinikithemba staff complement, who had never dealt with such 
volumes of PLHIV, to work together as a team focusing on the requirements of one 
specific preparation step for a defined batch of PLHIV per week. This was over and 
above managing the ever increasing numbers of PLHIV already on ART returning to the 
clinic for their ART monitoring visits.  
As the numbers of PLHIV grew, clinical staff had to consult growing numbers of PLHIV 
on any given day and the waiting times during the day grew longer. Sinikithemba became 
recognised by the community as an ART initiation site and the stream of ART-eligible 
PLHIV entering the programme also increased, causing the booking lists for the first 
ART Literacy Session to get longer, with some psychosocial assessments being 
scheduled as far ahead as six months in advance. 
Initially as more clinically trained staff were employed and additional consulting rooms 
were created, the waiting list could be reduced by increasing the number of booking slots 
available for the first ART literacy session. However, management staff often faced a 
dilemma in when to make these additional slots available as calling previously booked 
PLHIV back to fill the additional new slots, increased administration, whilst allowing 
newly assessed PLHIV to fill the new vacant appointments slots, effectively allowed 
them to jump the queue ahead of previously booked PLHIV. 
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It was also difficult to gauge the effect of increasing the number of slots on the clinician’s 
capacity as there was a delayed effect of the increased work-load. Many factors including 
the number of PLHIV who adhered to their scheduled clinic visits or arrived 
unscheduled, the number of critically ill PLHIV seen on any given day, the number of 
staff absent or on leave, affected whether a the clinic was manageable or not. This made 
it difficult to ascertain the maximum number of clinical assessments that the clinic could 
manage per day. 
With the increasing length of the waiting list as more PLHIV entered the programme, an 
additional management dilemma was how to fit critically ill PLHIV with low CD4 counts 
below 50 or even 10 cell/uL into the programme. These PLHIV required fast-tracking 
through the system and emergency ART, but by doing so the less sick PLHIV who 
entered care earlier with higher CD4 counts were disadvantaged as the appointment 
bookings were taken up by these sicker PLHIV. 
By the end of 2006, the system and its administration had become unmanageable. 
Following a number of management meetings, a new system was proposed to process 
ART preparation PLHIV and reduce the ART preparation waiting time. 
3.2.4 Daily ART Preparation System 
The Daily ART Preparation System was implemented at the beginning of January 2007 
and there was six months of overlap with the old Batch System due to the numbers of 
PLHIV who had been booked on the Batch System waiting list. In July 2007 the Batch 
System had been completely phased out and all ART preparation was managed through 
the Daily ART Preparation System. 
The basic concept of the Daily ART Preparation System was to prepare PLHIV for ART 
at any stage of the process, every day, rather than at specific weeks in the month. The 
Sinikithemba administration system had become robust over the previous two years and 
the senior staff were experienced enough to manage the various ART preparation stages 
on the same day.  
 34
The preparation steps still had to be completed in sequence but the Daily System 
increased the number of ART literacy days per step from seven, one week a month, to as 
many working days as there were in the month. This system reduced the waiting time for 
PLHIV needing an ART literacy booking.  
Previously if a PLHIV entered care in the middle of the month of the Batch system and 
had missed the first ART literacy week at the beginning of the month, they had to wait 
until the next month or even a couple of months later before they could slot into the next 
ART literacy session. In the new system if the PLHIV missed the first ART literacy 
session for the day, they could come back the next day for next scheduled session. 
The number of bookings still had to be limited as on any given day all three literacy 
sessions had to be scheduled and the clinical and counselling staff could still only manage 
a limited total number of PLHIV per day. The staff also had to adjust to accommodate 
both ART preparation PLHIV at any stage in the ART preparation process as well as the 
ART initiated PLHIV returning for ongoing monitoring.  
However with more booking days available the booking delay never exceeded one 
month. In fact the reverse was experienced where some PLHIV did not feel ready to book 
so soon and chose to delay the ART preparation themselves until they felt ready to move 
on with the process. 
3.3 STUDY PERIOD 
The study period was from 1
st
 of July 2004, when the Sinikithemba received funding
6
 to 
rapidly expand the ART initiation programme, to the 31
st
 of December 2007 so as to 
include the change in the ART preparation system in 2007 and allow for comparison of 
the two ART preparation systems. During this study period other events were identified 
that may have affected the process of ART preparation and these are discussed in more 
detail in the statistical analysis section.  
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In order to allow time for ART-eligible PLHIV to either initiate ART or be defined as 
lost to care - which required at least six months from the last clinic visit - enough follow 
up time had to be scheduled into the study timeframes. Therefore the last day of data 
collection was the 31
st
 of July 2009 to allow for at least 18 months of follow-up time 
from the end of the study period.  
3.4 TYPE OF RESEARCH 
This study was classified as retrospective operational research.  
3.5 STUDY DESIGN 
An observational cohort study design was used.  
3.6 TARGET POPULATION 
The target population was adults
7
  living with HIV residing in the greater Durban 
Metropolitan Area, who are able to afford the user-fee to access care at the Sinikithemba 
HIV Clinic at McCord Hospital. 
3.7 STUDY POPULATION 
The study population included all  PLHIV registered at  Sinikithemba on the TrakCare
8
 
database from July 2004 to December 2007, with a CD4 count equal to or lower than 200 
cells/uL (which was the ART initiation policy at the time) within the study period. 
  
                                                 
7
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8
 Health Management Information System 
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3.7.1 Selection of study population 
As a retrospective review of data accessible in an electronic database, TrakCare, 
sampling was not necessary as all records meeting the inclusion criteria were extracted. 
Every PLHIV registered on TrakCare who met the following inclusion criteria was 
included in the study: 
• All PLHIV 15-years or older, registered on TrakCare within the study period, July 
2004 to December 2007; and 
• A baseline CD4 count equal to or lower than 200 cells/uL within the study period.  
Due to differences in the ART preparation, HIV-infected children less than 15-years old 
and HIV-infected pregnant woman were excluded from the study. 
3.8 DATA MANAGEMENT 
3.8.1 Ethics 
As a retrospective review, no intervention or contact with PLHIV was necessary by the 
Principal Investigator and the study had no direct impact on patient care. All patient 
records were anonymised and extracted data were stored on a single password protected 
computer. 
Ethical approval was obtained from the Biomedical Research Ethics Committee of the 
Nelson R Mandela School of Medicine South Africa, reference number BE142-08  and 




3.8.2 Data Source 
When Sinikithemba received funding
9
 for rapid scale up of ART services, the HMIS 
TrakCare database was implemented to manage patient records. Every visit to 
Sinikithemba and the reason for the visit is recorded along with relevant clinical 
information. This system is web-based and is updated real-time at every point of service 
delivery, including administration, laboratory and pharmacy services.  
As a comprehensive database, TrakCare was the only data source used for this study. 
Crystal Report Writer software was used to extract data from TrakCare and export the 
data into Microsoft Excel. Once validated, data were exported into statistical software 
packages for data analysis. 
Changes to the ART preparation system over time and how they affected pre-ART loss-
to-care were not explicit in the data collected and management memorandums and 
meeting minutes were referred to identify events or system changes that may have 
affected the pre-ART preparation process. 
3.8.3 Variables 
The key data elements required for the study were extracted from TrakCare on the 1
st
 of 
August 2009 and provided the data used to generate the variables needed for data 
description and analysis (see appendix Table 8.1). 
For example, the data element ‘Last ART Preparation Visit’ was used to create the 
variable ‘Lost-to-Care’. The variable was assigned a zero if PLHIV were in care within 
six months of the end of the study follow up period. At Sinikithemba there is no active 
follow up of pre-ART PLHIV who stop accessing care at the clinic, therefore if a PLHIV 
had not accessed care for six months or more prior to the end of the study follow up 
period they were defined as lost to care, and assigned a one in the database (see appendix, 
Table 8.2).   
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3.8.4 Reliability and Validity of Data Source 
Data updated on TrakCare are validated against clinic registers and patient files by the 
Sinikithemba Monitoring and Evaluation Department on a daily basis. Extraction reports 
generated from clinical, pharmacy and laboratory modules in the TrakCare database are 
then cross-referenced monthly to ensure data quality.  
In order to ensure the internal validity of the data extracted from TrakCare for the study, 
logical sorting and cross-checks were done with the extracted data to validate the 
extraction report. In addition to this random records were selected for back-checking 
against data entered into TrakCare database.  
Concerning external validity, the main limiting factor is the monthly user-fee charged to 
PLHIV. As a state-subsidized hospital, McCord Hospital accesses donor funding and 
charges patient fees to cover the balance of its operational cost. The patient fees charged 
are higher than those at state facilities, but less than that charged in the private sector. 
These factors as well as the Sinikithemba being a hospital based facility within an urban 
area, designed to comply with its main donor’s
10
 reporting requirements, limit the 
generalisability of the study results. 
3.9 SELECTION, RECALL AND INFORMATION BIAS 
As no sampling was done, selection bias was limited and with TrakCare data entry being 
done real-time, recall bias was also limited. However as changes to the ART preparation 
system and how they affected pre-ART loss-to-care were not explicit in the data 
collected, the effect of these events or changes on the ART preparation process could 
only be inferred and may have caused information bias. For example it was not possible 
to distinguish which PLHIV were booked for ART preparation through the Batch or 
Daily System during the six month period of overlap between the two systems in 2007, 
therefore these two systems had to be treated as mutually exclusive in the data analysis. 
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With TrakCare being an electronic system that has been customized and developed over 
time and with data-entry performed daily by a number of different service providers, 
inaccuracy due to human error, staff turn-over and training or system down-time can be 
expected and give rise to information bias. The Sinikithemba Monitoring and Evaluation 
Department crosschecks and the random data validation conducted on the extracted data 
for this study, limited the information bias within the study dataset. 
3.10 STATISTICAL ANALYSIS 
Variables were first summarised and described before the confirmatory analytic steps 
were taken to measure associations (Table 8.1, annex). The associations outlined in the 
study objectives, examined at the p<0.05 significance level, were first measured through 






 statistical software were used to conduct the statistical analysis for 
this study. The University of KwaZulu Natal, Department of Public Health Medicine 
biostatistician, Ms Tonya Esterhuizen was consulted to ensure the correct statistical tests 
were used and that the interpretation of the statistical analysis and results was 
appropriate. All statistical tests and processes were conducted by the Principal 
Investigator. 
The framework outlined in Table 3.1 was used to ensure each study objective and 
hypothesis was addressed and that the methods used for the statistical processing of data 
were adequately described. 
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Table 3.1: Data analysis framework for pre-antiretroviral therapy loss-to-care of 
people living with HIV at Sinikithemba HIV Clinic, July 2004 to December 2007. 
Exploratory analysis (descriptive) 
Objective 1: Describe the demographic and clinical characteristics of adult PLHIV in the 
ART preparation process 
Objective 2: Quantify loss-to-care at each stage of ART preparation 
Objective 3: Measure patient waiting times between each stage of the ART preparation 
process 
Confirmatory analysis (analytic) 
H01 Objective 4: Analyse the association between age, gender, CD4 count and pre-ART 
loss-to-care 
H02: Pre-ART Loss-to-Care is different at different ART preparation steps 
H03 Objective 5: Analyse the association between psychosocial and clinical delays and 
pre-ART loss-to-care 
H04 Objective 6: Analyse the association of pre-ART waiting times between steps of the 
ART preparation process and pre-ART loss-to-care 
H0 New Objective 7: Investigate any other associations which may arise from the analysis 
of the data 
Objective 8: Recommendations for improvements for ART preparation at Sinikithemba 
HIV Clinic based on the results of the study. 
 
3.10.1 Exploratory data analysis 
As a retrospective cohort study it was necessary to firstly define the outcome and 
exposure variable within the data collected. As the purpose of the study was to define 
pre-ART loss-to-care, the outcome variable was defined as ‘Lost-to-Care’. 
All PLHIV who had a CD4 count equal to or less than 200 cells/uL in the dataset were 
sorted according to their last clinic visit date. If they were still accessing care by the end 
of the study period they were assigned a zero for ‘still in care’. If they had no clinic visit 
for six months or more prior to the end of the study period, they were assigned a one for 
‘lost to care’, as pre-ART PLHIV are not actively followed up at Sinikithemba so the 
reason for non-attendance was not available. The outcome group, ‘Lost-to-Care’ is an 
independent group from the ‘Not Lost-to-Care’ group. 
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Due to the length of follow-up time allowed in the study period, one-and-a-half years, 
every study subject had either initiated ART or had been lost to care (at least six months 
since last contact at the clinic with reason for non-attendance unknown) by the time data 
were extracted which meant there were only two outcome groups defined. 
It was then necessary to define the exposure variables according to the specific objectives 
outlined in the study protocol: 
• Age at ART-eligibility within the study period; 
• Gender; 
• Baseline CD4 count result equal to or lower than 200 cell/uL; 
• Each ART preparation step completed; 
• Waiting time between each ART preparation step completed; and 
• Clinical or psychosocial consultation delays.  
Finally, before any data analysis could take place two important aspects of each variable, 
namely the variable type and the distribution of the data, were established in order to 
match the underlying assumptions of the statistical tests chosen for each variable.  
The one-sample Kolmogorov-Smirnov test was used to test the distribution of the 
continuous exposure variable types and each of these variables was found to be non-
normally distributed. Therefore the median and interquartile range (IQR), rather than the 
mean and standard deviation, were chosen as the preferred measure of central tendency to 
describe continuous variables.  




3.10.2 Describing demographic and clinical characteristics   
In order to describe the demographic and clinical characteristics of the study subjects, the 
age at enrolment, gender and baseline CD4 count of PLHIV were analysed. 
The proportion and 95% Confidence Interval for gender difference and the median age 
were calculated to describe the precision of demographic characteristics of the cohort, 
whilst the median baseline CD4 count was calculated to summarise the clinical 
characteristics.  
3.10.3 Describing Loss-to-Care at each stage of ART preparation 
Data on the last clinic visit and visit category were extracted from the database. PLHIV 
who had initiated ART and were attending the clinic for monthly follow-up visits were 
assigned the category ‘ART started’ and the rest of the PLHIV who were ‘Lost-to-Care’, 
were sorted according to the last ART preparation step they had attended. 
From sorting PLHIV according to the last clinical visit, it was possible to calculate the 
proportion and 95% Confidence Interval of those who were lost to care at each step in the 
ART preparation pathway.  
3.10.4 Describing ART preparation waiting times 
Having the date and category of first visit, , the date of the baseline CD4 count and the 
dates and categories of all subsequent visits, allowed for the calculation of waiting or 
delay time (in days) between each ART preparation step for each PLHIV. 
If a PLHIV completed a specific ART preparation step more than once, the date of the 
last time that step was performed was used for the calculation as this indicated their 
progression to the next step. 
At each step, the waiting time data distribution was skewed and so the median waiting 
time in days was calculated with the interquartile range. 
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3.10.5 Exploring an additional variable of interest 
Exploratory data analysis assisted the researcher to get familiar with the data and new or 
unexpected patterns or relationships may emerge through the process, generating new 
hypotheses (25).  
In working with the clinic visit dates, it became clear that certain PLHIV had entered care 
prior to being ART eligible and had returned to the clinic for CD4 monitoring prior to 
becoming eligible for ART. As the data were available for analysis, it was decided to 
include this as an additional hypothesis to test during the data analysis: 
PLHIV who accessed HIV care prior to being ART-eligible for pre-eligibility 
care, are less likely to be lost to care than PLHIV who entered HIV care when 
they were ART-eligible. 
The median time in pre-eligibility care and the median first CD4 count result prior to 
ART eligibility were calculated during the exploratory data analysis. 
3.10.6 Confirmatory data analysis 
Due to the continuous variables being non-normally distributed, non-parametric Mann-
Whitney (Two Independent Sample Test) and Kruskal-Wallis (more than two 
independent samples) statistical tests were chosen. The categorical variables were tested 
with Chi-square tests, namely the Fisher’s Exact test. 
Establishing a statistically significant difference in the outcome, dependent on the 
exposure, is important for analysing relationships between variables but it does not 
necessarily have clinical or public health significance. Therefore it is important to take 
the analysis one-step further and calculate the association between the exposure and 
outcome variable. In cohort studies, the preferred measure of association is the incidence 
risk ratio or relative risk. 
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In order to calculate relative risks, data needs to be categorical for the 2X2 Contingency 
Table calculations. With continuous numeric variables, this is possible by disaggregating 
the continuous data into smaller meaningful categories that can be compared for risk. For 
example, age can be broken down into age-bands that can be compared against each other 
for differing risks estimates.  
Once the bivariate analysis was completed and it was clear which variables were 
associated with pre-ART loss-to-care, stratification and multivariate analysis was done to 
establish which variables had inter-relationships that were confounding the associations. 
3.10.7 Demographic and clinical factors associated with pre-ART Loss-to-Care 
Statistically significant differences in loss-to-care associated with the demographic and 
clinical exposure variables were tested. As a categorical variable, Chi-square Tests were 
used for gender and the Mann-Whitney Test for non-parametric continuous variables was 
used for enrolment age and baseline CD4 count. 
During the analysis of the continuous variables, age at enrolment and baseline CD4 
count, significant differences in the outcome based on various categories within each 
exposure variables were tested. These categories were then used for relative risk 
calculations (see appendix Table 8.2).  
For convenience, three ten-year age-bands were defined for PLHIV between 30 and 50-
years-old, the 15 to 29-year-olds were grouped together, and all PLHIV 50-years-old or 
older were grouped together.  
Initially four CD4 count categories were defined, into 50 unit bands for convenience. 
However, relative risk calculations need to provide information that helps make clinical 
decisions and these arbitrary categories were not clinically significant.  
Based on the CD4 median calculations, CD4 counts were divided into a 0 to 50 cell/uL 
category and a 51 to 200 cell/uL category. This made clinical sense given the fact that 
most PLHIV with CD4 counts less than 50 cells/uL were fast-tracked to initiate ART.  
 45
The association between pre-eligibility care and pre-ART loss-to-care was calculated and 
the relative risk of being lost to care was compared against those PLHIV who had had 
pre-eligibility CD4 monitoring care or not. 
3.10.8 ART preparation delays associated with pre-ART Loss-to-Care 
Initially when the data were processed, it was clear that there weren’t sufficient data on 
clinical and psychosocial delays to create a variable to analyse the association between 
these delays and pre-ART loss-to-care. 
However, during exploratory data analysis to describe pre-ART loss-to-care at each of 
the pre-ART steps, a sub-group of PLHIV were identified who were lost to care at a 
clinical or psychosocial visit that was not a defined pre-ART preparation step. In most 
cases, ART was commenced at the third ART literacy visit, however some PLHIV have 
ART initiation delayed at this visit and are then either lost to care or initiate ART later. 
It was only possible to analyse these delays at the third and final ART literacy step before 
ART initiation. When PLHIV who were delayed at earlier ART preparation steps, 
progressed onto the next ART preparation step rather than being lost to care, the delay 
was masked and could not be analysed.   
Chi-square tests were done to test whether there was a statistically significant difference 
in pre-ART loss-to-care between PLHIV who had a delay in ART initiation at the third 
ART literacy in comparison to those PLHIV with no delays. The association was 
assessed using the relative risks.   
3.10.9  ART preparation steps associated with pre-ART Loss-to-Care 
Describing the proportion of PLHIV lost to care at each ART preparation step during the 
exploratory analysis was an important step in preparation for analysing the association 
between pre-ART loss-to-care and the other ART preparation steps. 
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These proportions were used in 2X2 Table to perform Chi-square tests and calculate the 
related relative risks of pre-ART loss-to-care at each ART preparation step.  
Once it was clear at which step the greatest risk of loss-to-care occurred, it was possible 
to analyse waiting time between ART preparation steps, which was hypothesized to be 
associated with pre-ART loss-to-care. 
3.10.10 ART preparation waiting times associated with pre-ART Loss-to-Care 
Because it takes time to complete the required steps to initiate ART and that PLHIV lost 
to care did not complete the final ART preparation step, PLHIV lost to care in effect 
remained in the system for a shorter time than those who initiated ART. Therefore, 
despite having a time variable available it was not meaningful to calculate rate ratios and 
plot the exposure variables against the time to outcome on a Kaplan Meier plot as the 
survival curve did not reflect the true situation. 
In order to test the hypotheses that pre-ART loss-to-care was associated with the waiting 
time or delays between ART preparation steps, it was necessary to calculate the waiting 
time for each PLHIV, between each ART preparation step. Without the Sinikithemba 
booking lists available to measure this across the three-and-a-half year study period, the 
only way to determine these waiting times was to measure the time taken per PLHIV 
between each preceding and successive step that was completed.  
For the PLHIV lost to care, this calculation was not possible at their final ART 
preparation step, as they were lost to care before completing that particular step. This 
made it impossible to calculate the relative risks of pre-ART loss-to-care associated with 
the waiting time between ART preparation steps. 
This problem was overcome by assuming that PLHIV who were ART eligible at the same 
time, whether those lost to care or ART initiated, would have had similar waiting times 
for ART initiation. Therefore, all PLHIV were grouped together according to the month 
they were confirmed to be ART-eligible, their enrolment month, and the median waiting 
time for each ART preparation step was calculated for each monthly enrolment group. 
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An area graph was plotted showing the overall time from eligibility to outcome for each 
monthly enrolment group in comparison to the waiting time for each of the first three 
ART preparation steps (CD4 to psychosocial assessment, psychosocial assessment to the 
first ART literacy session and the time between the first and second ART literacy 
session). 
Given that the ART preparation system was changed in January 2007 in an attempt to 
reduce waiting times for ART initiation, it was important to analyse what affect this 
change had on ART preparation waiting time and pre-ART loss-to-care. Although there 
was a period of overlap between the two systems, it was not possible to delineate this in 
the data and they were therefore treated as mutually exclusive systems due to these data 
limitations. 
Known changes to the ART preparation system throughout the three-and-a-half year 
study period were also plotted against the area graph in order to assess whether these 
changes had an effect on the ART preparation waiting times. As the effect of these 
changes was not explicit in the data collected, the effect on waiting time could only be 
inferred by comparing the corresponding waiting time for ART initiation when these 
events occurred. 
The area graph provided a snapshot view of the two ART preparation systems and 
assisted in identifying differences in ART preparation times between the two systems. 
Fisher’s Exact Chi-square test was then used to test whether the January 2007 change in 
the ART preparation system made a statistically significant difference to ART 
preparation times and pre-ART loss-to-care. 
Each of the variables shown to be associated with pre-ART loss-to-care in the bivariate 
analysis were analysed across the two different ART preparation systems. Mantel-
Haenzel adjusted relative risks were calculated in order to understand the affect that the 
ART preparation system changes had on pre-ART loss-to-care and associated variables. 
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In addition to this, the median waiting time per month for each ART preparation step 
were categorized according to those above or below the overall median waiting time per 
step. This made it possible to calculate relative risks of pre-ART loss-to-care per waiting 
time for each ART preparation step and analyse whether enrolment months with higher 
median waiting times had higher proportions of PLHIV lost to care.  
3.10.11 Multivariate analysis 
The statistically significant variables shown to be associated with pre-ART loss-to-care 
through bivariate analysis were advanced to multivariate analysis in order to test 
confounding between variables. 
Each of the associated exposure variables were analysed through logistic regression 
against the binary outcome of pre-ART loss-to-care. Those exposure variables, which had 
affected pre-ART PLHIV, were analysed together. The exposure variables, which 
affected only a subset of pre-ART PLHIV, were analysed separately due to the different 
number of observations per exposure variable.  
Based on the findings from the statistical analysis, recommendations for improvement to 
the ART preparation system are made in the discussion chapter.  
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4 CHAPTER IV: RESULTS 
 
4.1 INTRODUCTION  
In this chapter, the results of the data summary and the analysis conducted for this study 
are described and presented. The framework used for processing the data are presented in 
the methods section (Table 3.3). The most important results for each study objective and 
hypothesis are presented in appropriate tables and figures and described in the text. 
4.2 EXPLORATORY DATA ANALYSIS 
4.2.1 Describing demographic and clinical characteristics  
The baseline characteristics of the 5470 people living with HIV (PLHIV) registered at 
Sinikithemba HIV Clinic reveal that more than half, 54% (2979) of antiretroviral therapy 
(ART) eligible PLHIV in the period July 2004 to December 2007, were lost to care prior 
to initiating ART (Table 4.1). A larger proportion of females, 56% (3073) accessed ART 
preparation services than males, with the median CD4 count being 68 cells/uL at entry to 
the programme. Almost half (42%) of ART-eligible PLHIV had a baseline CD4 count 
below 50 cells/uL. 
Two exposure variables of interest for this study were the number of PLHIV who entered 
pre-eligibility care and those PLHIV who were delayed in starting ART at the third ART 
literacy visit. Only 266 (5%) of the 5470 study subjects accessed CD4 monitoring 
services at Sinikithemba prior to being ART eligible, meaning that 95% (5204) of the 
ART eligible PLHIV included in this study, were ART eligible at the time of their first 




Table 4.1: Baseline characteristics of pre-antiretroviral therapy people living with 
HIV at Sinikithemba HIV Clinic, July 2004 to December 2007 (n=5470). 
      n   
Pre-ART Loss-to-Care 2979 (54%) 
Demographic characteristics  
  Male 2397 (44%) 
  Age, median in years (IQR)      35 (30-41) 
Baseline CD4 cell count, median cells /uL (IQR)      68 (25-131) 
Pre-Eligibility Care given  266 (5%) 
Attended third ART literacy  2739 (50%) 
   ART Initiation delay at third ART literacy 633 (23%) 
ART preparation system  
  Batch System (July 2004 – December 2006) 3976 (73%) 
  Daily System (January 2007 – December 2007) 1494 (27%) 
Time from Eligibility to Outcome, median in days (IQR) 37 (5-95) 
Data are number (%) unless otherwise indicated. IQR, Interquartile range. 
Age Mean: 36.15 years, standard deviation 8.77 
Baseline CD4 cell count Mean: 79.59 cell/uL, standard deviation 59.94 
Eligibility time to Outcome Mean: 71.74 days, standard deviation 121.4 
In all, 633 (23%) of the 2739 ART eligible PLHIV who made it to the third ART literacy 
step, were delayed in progressing to the next step for either clinical or psychosocial 
reasons. Data will be presented in the confirmatory data analysis section showing 
whether these were significant factors associated with pre-ART loss-to-care. 
The median time taken for an ART eligible PLHIV to reach an outcome of either ART 
initiation or being lost to care was 37 days. The wide interquartile range of 5 to 95 days 
indicates that there was considerable variation in length of care for PLHIV being 
prepared for ART, with some of those eligible for ART only remaining in care for 5 days 
or possibly less. 
As the study time-period was selected to include two different ART preparation systems, 
the batch and Daily System, PLHIV were categorised according to the system they 
entered ART preparation care. The data were stratified on this variable to control for 
differences in these two systems. These results are described with the confirmatory data 
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analysis results. 
4.2.2 Describing Loss-to-Care at each stage of ART preparation 
A total of 14 487 people were registered at Sinikithemba during the study period, July 
2004 to December 2007. This included 4063 (28%) people who registered at the clinic 
for HIV testing and who were tested HIV negative. Of all the people registered at 
Sinikithemba in the study period, 72% (10 424) were HIV-infected (Figure 4.1). Almost 
half of these 4954 (48%) PLHIV, were lost to care before having a CD4 count done to 
determine their eligibility for ART. 
The remaining 5470 (52%) PLHIV were classified as ART-eligible defined as having a 
CD4 count of 200 cell/uL or less, which could have been tested at Sinikithemba or 
elsewhere as long as there was proof of the CD4 result. Only 266 of these ART eligible 
PLHIV were not ART eligible when they registered with the programme. Their CD4 
count was monitored until they became eligible, at which point they were then counted 
with the rest of the 5470 PLHIV who were ART eligible at their first visit to 
Sinikithemba. 
Of the 5470 PLHIV, 625 (11%) PLHIV did not even return to the clinic to collect their 
CD4 count results. ART eligible PLHIV were lost to care at every step in the ART 
preparation process with the highest proportion of 1889 (39%), being lost to care at the 
psychosocial assessment step. The lowest proportion of PLHIV lost to care occurred at 
the next steps; 158 (5%) at the first ART literacy step and 58 (2%) at the second ART 
literacy step.  
A further 248 (9%) of the 5470 ART-eligible PLHIV were lost to care at the third ART 
literacy step with only 2491 PLHIV, less than half (46%) of those ART-eligible  
managing to complete the preparation process and initiate ART at the clinic. 
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Figure 4.1: Flow of people living with HIV through the antiretroviral therapy 
preparation process at Sinikithemba HIV Clinic, July 2004 to December 2007. 
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4.2.3 Describing ART preparation waiting times 
The median waiting times between each step of the ART preparation process were 
calculated (Figure 4.1). The median time between having a CD4 test and receiving the 
CD4 count results and having a psychosocial assessment, was six days. Again, the 
interquartile range (4 to 21) demonstrates that there was considerable variation in the 
length of time between these steps.  
The psychosocial assessment to first ART literacy session had the longest median waiting 
time of 31 days, whilst the waiting time between the first, second and third ART literacy 
steps was 7 days (Figure 4.1). As the waiting time of zero days between the third ART 
literacy session and ART initiation indicates, most PLHIV initiate ART at the third ART 
literacy step, (Figure 4.1). The association between these waiting times and the 
proportion of PLHIV lost to care at these ART preparation step will be discussed in the 
confirmatory data analysis section. 
The overall median time from ART eligibility to ART initiation was 89 days, IQR (55 to 
130) and the overall median time from ART eligibility to pre-ART loss-to-care was 5 
days, IQR (2 to 19). 
4.3 CONFIRMATORY DATA ANALYSIS 
4.3.1 Demographic and clinical factors associated with pre-ART Loss-to-Care 
Baseline CD4 count was found to be significantly associated with pre-ART loss-to-care, 
(p<0.001, Mann-Whitney Two Independent Sample Test). Of the four baseline CD4 
count categories 1375 (25%) of PLHIV with a baseline CD4 count in the CD4 category 
0-50 cells/uL were lost to care (Figure 4.2). In each of the three other baseline CD4 count 
categories, PLHIV loss-to-care was no more than 11% per category, 562 (11%), 503 




Figure 4.2: Loss-to-Care percentage among antiretroviral therapy-eligible people 
living with HIV based on baseline CD4 result at Sinikithemba HIV Clinic, July 2004 
to December 2007 
In order to test this exposure variable in a way that is clinically significant, baseline CD4 
counts were categorized into two categories, PLHIV with a baseline CD4 count below or 
equal to 50 cells/uL and those PLHIV with a baseline CD4 above 50 cells/uL. 
PLHIV having a baseline CD4 count below 50 cells/uL were at a significantly greater 
risk of being lost to care than those PLHIV with a higher baseline CD4 count (p<0.001, 
Fishers Exact Chi-square Test), with a relative risk of 1.18, (95% Confidence Interval 
(CI): 1.12 to 1.24). 
Gender was also tested and male gender was significantly associated with pre-ART loss-
to-care with a relative risk of 1.08 (95% CI: 1.03 to 1.13) (p<0.02 Fishers Exact Chi-
square Test). Age at enrolment was not statistically associated with pre-ART loss-to-care 
(p=0.195, Mann-Whitney, Two Independent Sample Test).  






































No Loss to Care
 
4.3.2 Pre-eligibility care associate
Study PLHIV who had accessed HIV care prior to being eligible for ART and had 
undergone CD4 monitoring until they were ART eligible were identified 
exploratory data analysis. Although there were only 
who met this criteria (Figure 4.3
a statistically significant protective 
Fisher Exact Chi-square Test).
 
Figure 4.3: The proportion, 
with HIV who accessed pre
December 2007. 
The PLHIV who accessed pre
relative risk of being lost to care 
eligibility care was protective against pre
these PLHIV was 257 cells/uL at their first CD4 count test at 
median time spent in care prior to being ART
(median of 257 days, IQR 116 
No Pre-eligibility Care: (5204) 95%
d with pre-ART Loss-to-Care 
during the 
266 (5%) PLHIV out of 5470 PLHIV 
), this positive health-seeking behaviour was found to be 
factor associated with pre-ART loss-to-ca
 
CD4 median and waiting time median of people living 
-eligibility care at Sinikithemba HIV Clinic, J
-eligibility care, in comparison to those who did not,
of 0.66, (95% CI: 0.56 to 0.77), meaning that pre
-ART loss-to-care. The median CD4 count
Sinikithemba and the 
-eligible was approximately nine months 
to 474). 










uly 2004 to 






4.3.3 ART initiation delay
Another subset of PLHIV of interest
at the third ART literacy (Figure 4.4
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(7 to 52) (Figure 4.5). 
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4.3.4 ART preparation steps associated with pre-ART Loss-to-Care 
The proportion of pre-ART PLHIV lost to care at each ART preparation step was 
calculated with the associated relative risk (Figure 4.5). Each step was significantly 
associated with pre-ART loss-to-care (p<0.001, Fishers Exact Chi-square Tests). The 
greatest relative risk of loss-to-care is associated with the step from psychosocial 
assessment (RR 3.08, 95% CI 2.82 to 3.36, p<0.001, Fishers Exact Chi-square Test). The 
step with the next greatest risk of pre-ART loss-to-care occurs when there is a clinical or 
psychosocial delay between the third ART literacy session and ART initiation, (RR 2.08, 
95% CI: 1.74 to 2.42, p<0.001, Fishers Exact Chi-square Test). 
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Figure 4.5 Loss-to-Care risk associated with antiretroviral therapy preparation 
steps for people living with HIV at Sinikithemba HIV Clinic, July 2004 to December 
2007. 
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The ART preparation step with the longest median waiting time per month for the period 
July 2004 to January 2007 is seen between the psychosocial assessment to first ART 
literacy step and the median time from ART eligibility to outcome appears to have a 
similar trend, (Figure 4.6).  
In January 2007, the median waiting time for the first ART literacy session decreases 
sharply but the waiting time for the second ART literacy median waiting time increases. 
From January 2007, the median ART-eligibility to outcome time appears to mirror the 
waiting time for the psychosocial assessment and second ART literacy session. 
The changes in median waiting time between the first three ART preparation steps 
correspond with the change made at Sinikithemba from the Batch ART Preparation 
System to the Daily ART Preparation System in January 2007.  
The area graph also demonstrates the effect of increasing or decreasing the number of 
available ART preparation slots on the waiting time between ART preparation steps. In 
February 2004, due to a funding crisis, ART preparation slots were reduced and this 
corresponded with a spike in the first ART literacy waiting time. Ultimately, all ART-
eligible PLHIV were referred to other ART initiation sites during the funding crisis and 
this then corresponded with a slump in the waiting time for the first ART literacy session.  
Again, in September 2006 due to funding problems, the ART preparation slots were 
reduced and the graph shows a corresponding increase in waiting time from psychosocial 
assessment to the first ART literacy session.  
The area graph also demonstrates the effect of the change in laboratory used by the clinic 
in 2007 when Sinkithemba was granted access to the National Health Laboratory System. 
The benefit of this change was that the cost of laboratory testing was reduced and CD4 
tests were offered to PLHIV free of charge. However the turn-around time for CD4 
results increased from the 6day turn around available from the previous private laboratory 
to a three-week turn-around time with the National Health Laboratory System.  
 61
Table 4.2: Stratification of variables associated with the Loss-to-Care across two 
antiretroviral therapy preparation systems at Sinikithemba HIV Clinic, July 2004 to 
December 2007. 
         Batch System 
               N (%) 
 Daily System 
       N (%) 




ART preparation system 3976 (73) 1494 (27) - - - 
Pre-ART Lost to Care 2169 (55) 810 (54) P =0.83 - - 
Demographic characteristics      
  Male 1736 (44) 661 (44) P =0.60 - - 
Baseline CD4 cell count, median cells/uL (IQR) 62 (22-127) 82 (32-138) P<0.001 - - 
  CD4 count ≤ 50 cells/uL, median cells/uL (IQR) 1765 (44) 538 (36) P<0.001 1.18 
(1.12 – 1.24) 
1.18 
(1.12 – 1.61) 
Pre-Eligibility Care 131 (3) 135 (9) P<0.001 0.66 
(0.56 –0.77) 
0.66 
(0.56 – 0.77) 
ART Initiation delay at ART literacy 3 409 (10) 224 (15) P<0.001 2.18 
(1.52 – 3.13) 
2.21 
(1.55 -3.16) 
ART Preparation Step Loss-to-Care      
   Baseline CD4 Loss-to-Care 2169 (55) 810 (54) P<0.001 1.12 
(1.13 0 1.32) 
1.12 
(1.10 – 1.14) 
  Psychosocial Assessment Loss-to-Care 1811 (45) 543 (36) P<0.001 3.08 
(2.82 – 3.26) 
3.08 
(2.91 – 3.29) 
  ART literacy 1 Loss-to-Care 277 (7) 188 (13) P<0.001 1.43 
(1.25 – 1.63) 
1.43 
(1.24 – 1.63) 
  ART literacy 2 Loss-to-Care 218 (5) 89 (6) P<0.03 1.20 
(1.02 – 1.40) 
1.20 
(1.02 – 1.40) 
  ART literacy 3 Loss-to-Care 178 (4) 70 (5) P<0.001 2.08 
(1.74 – 2.48) 
2.08 
(1.74 – 2.48) 
ART Preparation Waiting time, median days (IQR) 31 (4-95) 47 (7-95) P=0.001 - - 
  CD4 count to PSA, median days (IQR) 5 (3-8) 22 (6-37) P<0.001 - - 
  PSA to ART Literacy 1, median days (IQR) 58 (24-81) 4  (1-7) P<0.001 - - 
  ART Literacy 1 to 2, median days (IQR) 7 (7-7) 26 (19-55) P<0.001 - - 
  ART Literacy 2 to 3, median days (IQR) 7 (7-7) 7 (7-7) P<0.001 - - 
  ART initiation delay, median days (IQR) 19 (7-49) 19 (10-42) P =0.5 - - 
RR, relative risk; CI, Confidence Interval; IQR, Interquartile range.  
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Despite these indications of ART preparation waiting time being affected by changes to 
the ART preparation system, no statistically significant difference in pre-ART loss-to-
care between the Batch ART Preparation System  and the  Daily ART Preparation 
System was found (p =0.83, Fisher Exact Chi-square Test, Table 4.2). 
In order to understand this better, each exposure variable that was found to be statistically 
associated with pre-ART loss-to-care by bivariate analysis was stratified across the two 
ART preparation systems and compared (Table 4.2). 
No statistically significant difference in gender between the two ART preparation 
systems was found (p = 0.60, Fishers Exact Chi-square Test). However there was a 
statistically significant difference in the baseline CD4 count, with the Daily System 
having a higher CD4 median by twenty units (82 cells/uL) than the Batch system (62 
cells/uL), (p<0.001, Mann-Whitney Two Independent Sample Test).  
The proportion of PLHIV with a CD4 count less than 50 cell/uL in the Daily System, 538 
(36%) was eight percent less than that of the Batch system, 1765 (44%). This was also 
found to be a statistically significant difference, (p<0.001, Fishers Exact Chi-square 
Test). However, there was no difference in the crude and adjusted relative risk of being 
lost to care when CD4 count was less than 50 cells/uL. Both the crude and adjusted 
relative risks associated with pre-ART loss-to-care were statistically significant, 
(p<0.001, Fishers Exact Chi-square Test). 
Pre-eligibility care was significantly different between the two ART preparation systems, 
with six percent more PLHIV accessing CD4 monitoring services prior to being ART-
eligible in the Daily System, 135 (9%), than the Batch system, 131 (3%).  
There was no statistically significant difference in the CD4 counts of these PLHIV. 
However the time spent in pre-eligibility care was significantly different, (p <0.001, 
Fishers Exact Chi-square Test) with the median time in pre-eligibility care in the Daily 
System (397 days, IQR: 158 to 628) being more than double that of the Batch system 
(188 days, IQR:98 to 336). 
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When comparing ART initiation delays at the third ART literacy session between the 
Batch and Daily System, there was a slight change in the adjusted relative risk from 2.18 
to 2.21, (p<0.001, Fishers Exact Chi-square Test). Unlike the Batch system, ART 
initiation delays at the third ART literacy visit were not associated with pre-ART loss-to-
care in the Daily System.  
Analysis of the association of pre-ART loss-to-care with the different ART preparation 
steps and the waiting times between these steps, stratified by the Batch and Daily ART 
Preparation Systems provided surprising results.  
The changes in the median waiting time per ART preparation step and the numbers of 
pre-ART PLHIV lost to care at each ART preparation step were significantly different 
across the two ART preparation systems (p<0.001 using Mann-Whitney Two 
Independent Sample Test for waiting time and Fishers Exact Chi-square Test for loss-to-
care).  
However, despite these statistically significant differences between the two ART 
preparation systems, the relative risks of pre-ART PLHIV being lost to care at each step 
did not change. 
Whilst the proportion of pre-ART PLHIV lost to care after the baseline CD4 count test 
and the psychosocial assessment step decreased, the proportion of pre-ART PLHIV lost 
to care after the three ART literacy sessions increased when comparing the Batch and 
Daily ART preparation steps. All of these differences were found to be statistically 
significant differences across the two ART preparation systems, (p<0.001 Fishers Exact 
Chi-square Test). 
The Psychosocial Assessment waiting time was also significantly different between the 
two ART preparation systems, with the median waiting time decreasing from 58 days to 
four days in the Daily System, (p<0.001, Mann-Whitney Two Independent Sample Test).  
The difference in waiting time between the second and third ART Literacy sessions was 
also significant, but in the opposite direction with the waiting time increasing from 7 to 
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26 days, (p<0.001, Mann-Whitney Two Independent Sample Test). 
Due to there being no statistically significant difference in pre-ART loss-to-care when 
comparing the two ART preparation systems, the only way to analyse whether the 
waiting time between ART preparation steps was associated with pre-ART loss-to-care 
was to calculate the relative risk of pre-ART loss-to-care per monthly enrolment group.  
The only ART preparation step that was associated with pre-ART loss-to-care, when 
comparing the median waiting time per monthly enrolment group was the psychosocial 
assessment to the first ART literacy step. The median waiting times per enrolment group 
were categorised according to the overall median waiting time of 31 days and tested to 
assess whether pre-ART loss-to-care per enrolment group was higher when the median 
waiting time was higher than 31 days. 
The relative risk of pre-ART loss-to-care per enrolment group when the median waiting 
time between psychosocial assessment and the first ART literacy session was greater than 
31 days, was 1.22 (95% CI:1.16 to 1.25, p<0,05 Fishers Exact Chi-square test).  
The relative risk calculations for waiting time between the other ART preparation steps 
were not found to be statistically significant. 
4.3.6 Multivariate analysis 
Of all the exposure variables tested against the outcome variable of pre-ART loss-to-care, 
gender, baseline CD4 count, pre-eligibility care and the median waiting time between 
psychosocial assessment and the first ART literacy session per enrolment group, affected 
all pre-ART PLHIV in the study. 
Each of these exposure variables were individually tested and found to have a statistically 
significant association with pre-ART loss-to-care using logistic regression, (p<0.05. 
Generalised Linear Model for the Binomial Family). When these exposure variables were 
tested together using logistic regression again to control for confounding, each exposure 
variable was still found to be statistically significant, (p<0.05, Generalised Linear Model 
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for the Binomial Family, Table 4.3). 
Not all pre-ART PLHIV reached the third ART literacy step and therefore the exposure 
variable of ART initiation delay at the third ART literacy session could not be analysed 
along with the other exposure variables for all pre-ART PLHIV in the study (n=5470).  
The exposure variable ART initiation delay at the third ART literacy visit was compared 
against the other exposure variables using logistic regression for the subset of PLHIV 
who did reach the third ART literacy step (n=2739). The results showed that ART 
initiation delay at the third ART literacy visit remained statistically significant in its 
association with pre-ART loss-to-care, (p<0.05, Generalised Linear Model for the 
Binomial Family, Table 4.3).  
However the other exposure variables, gender, baseline CD4 count, pre-eligibility care 
and median waiting time between psychosocial assessment and the first ART literacy step 
per enrolment group, were no longer significantly associated with pre-ART loss-to-care. 
Table 4.3: Adjusted relative risk, using logistic regression, of variables associated 
with Loss-to-Care, at Sinikithemba HIV Clinic, July 2004 to December 2007. 
 Adjusted 
Relative Risk 
P-value 95% Confidence 
Interval 
N=5470 
Gender (male) 1.07 0.008 1.02 - 1.12 
CD4 count < 50 cell/uL 1.15 <0.001 1.19 - 1.21 
Pre-eligibility care 0.71 <0.001 0.60 - 0.83 
Psychosocial to first ART literacy median time > 31 days 1.22 <0.001 1.16 - 1.28 
N=2739 
ART initiation delay at third ART literacy session 2.18 <0.001 1.52 - 3.13 
Gender (male) 1.22 0.274 0.86 - 1.75 
CD4 count < 50 cell/uL 1.01 0.768 0.73 - 1.53 
Pre-eligibility care 0.58 0.282 0.22 - 1.56 
Psychosocial to first ART literacy median time > 31 days 1.35 0.102 0.94 - 1.94 
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5 CHAPTER V: DISCUSSION 
 
5.1 INTRODUCTION  
The demand for comprehensive HIV services is greater than the available supply, 
particularly for the provision of antiretroviral therapy. The resulting bottleneck in service 
delivery has considerable implications not only for the individual PLHIV and the overall 
management of the HIV epidemic, but also for resource management. This chapter 
outlines and discusses the main findings of the study in relation to the context of the 
literature available on the topic of loss-to-care in people living with HIV (PLHIV) that 
are eligible for antiretroviral therapy (ART).  
5.2 FINDINGS  
In line with the purpose of this study, the main finding from the data analysis is that more 
than half (54%) of the ART-eligible adults registered for HIV care at Sinikithemba HIV 
Clinic from July 2004 to December 2007, were lost to care prior to initiating ART.  
 
Statistical analysis identified six statistically significant exposure variables associated 
with this loss-to-care, which remained significantly associated with pre-ART loss-to-care 
even after controlling for confounding with logistic regression. Each of these exposure 
variables is discussed in the next sections of this chapter, highlighting the relevance of 
each and how it influenced pre-ART loss-to-care and ultimately management of the HIV 
epidemic. 
5.2.1 Proportion of ART-eligible PLHIV who are lost to care 
The recently released Department of Health National Antenatal Sentinel HIV and 
Syphilis Prevalence Survey in South Africa, 2009 found the HIV prevalence in adults (15 
to 49 years) to be 18%. This equals 5.3 million HIV-infected South African adults with 
almost 1.6 million of these PLHIV requiring ART.  
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KwaZulu Natal is still the province with the highest prevalence of HIV infection in ante-
natal woman, aged 15 to 49 years, of 39.5% and had a 0.9% increase reported in the year 
between 2008 and 2009. Even more concerning than this, is the fact that the eThekwini 
district, where McCord Hospital is situated, has an even higher prevalence of HIV 
infection in ante-natal woman, aged 15 to 49 years, than the province, of 41.5% (3). 
 
In relation to the similarly high pre-ART loss-to-care found at Sinikithemba of 54%, this 
does not paint a positive picture for the eThekwini district and the likelihood of the high 
HIV infection incidence being reversed in the near future. ART-eligible PLHIV are a 
particularly high-risk group with high viral loads and HIV transmission potential, as well 
as being immune-compromised and vulnerable to opportunistic infections or death (26).  
 
As the literature on retention of PLHIV in care grows, more studies are showing similar 
findings on pre-ART loss-to-care and are raising the alarm for the impact this will have 
on the current efforts to curb the HIV epidemic. If pre-ART attrition from HIV care goes 
unchecked, these ART-eligible PLHIV will continue to contribute to HIV incidence as 
well as the overwhelming burden of HIV morbidity and mortality experienced in the 
province. 
5.2.2 Demographic Characteristics of ART-eligible PLHIV lost to care 
The larger proportion of females (3073, 56%) in comparison to males (2397, 44%) 
accessing ART preparation at Sinikithemba is in line with current trends showing that 
more female adults access HIV care than males. A number of studies on retention in HIV 
care have shown that male gender is a risk factor for loss-to-care (27).  
As a statistically significant exposure variable associated with pre-ART loss-to-care, the 
importance of health systems adopting strategies targeted at getting and retaining males 
in HIV care is again highlighted. 
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Similar to other pre-ART loss-to-care studies, age at enrolment was not associated with 
pre-ART loss-to-care (28).The median age for ART-eligible PLHIV of 35 yrs was 
consistent with the 2009 HIV survey findings that the highest HIV prevalence is in the 30 
to 40 year age group. According to the survey this is attributed to the increased survival 
of those HIV positive PLHIV on ART, however this is not applicable for this particular 
group of pre-ART PLHIV (3).  
What is more likely is that a higher proportion of PLHIV in this age group are employed 
and able to pay the Sinikithemba clinic user-fee.   
5.2.3 Clinical Characteristics of ART-eligible PLHIV who are lost to care 
The median baseline CD4 count of 68 cell/uL for pre-ART PLHIV at Sinikithemba is low 
considering that the CD4 count threshold for ART initiation is 200 cell/uL. This is not 
surprising considering that 95% of the pre-ART PLHIV included in this study were ART 
eligible at their first clinic visit.  
Two possible reasons for this are the back-log created by the pre-2004 lack of access to 
ART in the public sector, and that Sinikithemba is a hospital-based facility, which may 
attract sicker PLHIV than the average ART clinic.  This raises the question of the clinical 
status of these PLHIV from delayed entry into care and presenting late for ART.  
Over the years since the rapid scale up of ART initiation, Sinikithemba has also 
developed a reputation for having shorter waiting times for ART initiation than most 
government clinics. One of the reasons for this could be the Sinikithemba fee. PLHIV 
who initially access care at another ART clinic rather than Sinikithemba may eventually 
put the required money together to come to Sinikithemba to try access treatment quicker 
after their health has deteriorated whilst waiting for ART elsewhere. 
Whatever the reason for this low baseline CD4 count, recent research findings show that 
the outcomes for such low baseline CD4 counts, are not good. A literature review on 
retention in care, conducted by Geng et al, described how the probability of remaining in 
care was lower for PLHIV with a baseline CD4 count lower than 50 cells/uL (12).  
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These PLHIV are most likely to die before initiating ART, and were found to have the 
lowest probability of initiating ART in the Free State cohort, even after accounting for 
the competing risk of death (28,29) 
With over 40% (2303) of  baseline CD4 count of PLHIV baseline CD4 count being less 
than 50 cells/uL, the study findings are consistent with other research findings that pre-
ART loss-to-care is associated with a baseline CD4 count less than 50 cells/uL. 
5.2.4 Pre-eligibility Care and ART-eligible PLHIV who are lost to care 
Unfortunately whilst the reverse is also true, accessing HIV care with a CD4 count higher 
than the ART initiation threshold is protective against pre-ART loss-to-care, only five 
percent of the ART-eligible PLHIV at Sinikithemba had entered HIV care prior to being 
ART eligible for ongoing CD4 monitoring. 
Interestingly the median first time CD4 count for these PLHIV was 257 cells/uL, not 
much higher than the ART initiation threshold during the study period. According to the 
current ART initiation guidelines, indicating ART initiation in pregnant or TB infected 
PLHIV, this subset of pre-eligibility or “in-eligible” PLHIV could have well been 
classified as ART eligible.   
Despite the numbers of PLHIV who accessed HIV care prior to being ART eligible being 
so low and their first CD4 count being so close to the ART initiation threshold, this was 
still a statistically significant exposure associated with pre-ART retention in care rather 
than pre-ART loss-to-care. 
The median time these PLHIV accessed HIV care prior to being ART-eligible was 265 
days, almost nine months, which could be one of the reasons for pre-eligibility care being 
protective against pre-ART loss-to-care. In that time, ongoing immunological and clinical 
evaluation through wellness care may well have protected the patient against the risk 
factors associated with late presentation and actually ‘pre-disposed’ these PLHIV to 
initiating ART at an optimal CD4 count (28) 
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As a study in Ethiopia indicated, the improved survival seen over time was related to 
PLHIV presenting earlier with less advanced disease causing PLHIV to initiate ART 
earlier with better outcomes (30). Whilst it would seem that it is critical that retention 
mechanisms incorporate interventions to get PLHIV into care as early as possible, a 
review of retention in care studies showed that both low and high CD4 counts were 
associated with pre-ART attrition (12). 
PLHIV with higher CD4 counts were more mobile and likely to be working and 
relatively well, which were themselves obstacles for remaining in care (12,30). 
Therefore, it is important that retention mechanisms are directed at the different 
categories of PLHIV, based on their need and motivation for accessing pre-ART care. 
5.2.5 ART initiation delay and ART-eligible PLHIV who are lost to care 
Pre-ART PLHIV who had ART initiation delayed at the third ART literacy step were 
more likely to be lost to care than those who had no ART initiation delay.  When all the 
statistically significant variables associated with pre-ART loss-to-care were tested against 
the variable ART initiation delay with logistic regression, ART initiation delay was the 
only variable that remained statistically significant in its association with pre-ART loss-
to-care. 
However when this variable was compared across the two ART preparation systems, 
ART initiation delays were no longer significantly associated with pre-ART loss-to-care 
in the Daily ART Preparation System. This was despite the fact that the same proportion 
of PLHIV had ART initiation delays per ART preparation system.  
One of the reasons for this change in association could be the relatively small size of this 
subset (n = 633), although this was not the case with the even smaller subset of PLHIV 
who had pre-eligibility care (n=266) and still had a significant association. 
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Another possible reason for ART initiation delay not being a statistically significant 
factor associated with pre-ART loss-to-care in the Daily ART Preparation System is that 
the shortened waiting time in the Daily System between the psychosocial assessment and 
first ART literacy step allowed PLHIV to have a clinical consultation earlier than those 
prepared through the Batch ART Preparation System. 
This change in the exposure variable from being highly significant in one subset of 
PLHIV to not being significant at all in another could be for the same reason that PLHIV 
who access pre-eligibility care are protected against pre-ART loss-to-care. Earlier access 
to clinical care, which was the case in the Daily ART preparation step, provides 
opportunity for immunological and clinical evaluation and reduces the risk of poor 
outcomes (12). 
Whereas PLHIV in the Batch ART Preparation System had much longer waiting times to 
a clinical consultation and possibly for those PLHIV, having one more delay at the third 
ART literacy session, which was most likely due to treatment of an opportunistic 
infection, may have been one delay too many. 
5.2.6 ART preparation steps and ART-eligible PLHIV who are lost to care 
Every time a pre-ART PLHIV has to return to the clinic there is a risk of the PLHIV 
being lost to care, this is demonstrated by the fact that every step in the ART preparation 
process at Sinikithemba, had a statistically significant associated relative risk.  
In the Department of Health’s book “Tried and Tested Models For The Scale Up Of HIV 
Prevention, Treatment And Care From South Africa And Beyond”, a whole section, is 
dedicated to “closing the gaps in HIV care”. One of the key areas highlighted and 
addressed is that of the bottlenecks that occur around ART preparation (26). 
Some of the models presented to streamline the ART preparation process propose that 
certain processes are “fast-tracked” such as providing access to CD4 count results 
without queues or delays and bundling services together to reduce the number of times a 
patient’s has to return to complete the process. 
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However, as was pointed out by the Free State study, most “immunosuppressed PLHIV 
cannot afford the luxury of extended pre-ART education” (28). It doesn’t matter what 
efforts are made to stream-line the process, the key targets of the process, ART-eligible 
PLHIV just are not in a position to ‘jump through all the hoops’ to complete the process. 
The current situation of extended waiting list for ART is that the process of ART 
preparation is ultimately rationing treatment to PLHIV who should all be initiated on life 
saving treatment. 
The PLHIV who were lost to care through this process are PLHIV who are classified as 
having acquired immunodeficiency syndrome (AIDS) based on their CD4 counts, the 
associated mortality with their low CD4 counts should provide the motivation needed for 
the development of a better system of preparing these PLHIV for ART. 
An evaluation of the efficiency of patient flow in three Ugandan clinics highlighted the 
fact that a PLHIV being prepared for ART could see up to five different service providers 
or more in one visit (31). The study recommended that the scale up of HIV services 
should be accompanied by evaluations aimed at maximising efficiencies, allowing more 
PLHIV into care without compromising the quality of care. 
This is not a simple task when faced with the huge demand for ART, with such limited 
resources but one of the critical areas that could be addressed is the actual process of 
preparing PLHIV for ART. Wagner et al showed with mathematical modelling that just 
by reducing the number of ART preparation sessions by two could reduce by half, the 
numbers of ART preparation PLHIV seen in the clinic per day (32). 
As was pointed out in the Free State study there has been no formal evaluation of the 
ART preparation process and potential alternatives to preparing ART-eligible PLHIV for 
lifelong HIV treatment (28). 
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5.2.7 ART waiting time and ART-eligible PLHIV who are lost to care 
Analysis of waiting time for ART initiation is not easily done because the outcome 
variable – loss-to-care, masks the exposure variable, waiting time when analysed at the 
ART preparation step at which a PLHIV was lost to care. Retention is also a longitudinal 
exposure with time being a confounding factor. It is difficult to draw causal conclusions 
about associations as these are ever changing (12). 
However the median waiting times between ART preparation steps and the overall 
waiting time from ART eligibility to outcome were calculated for this study and provide 
certain important insights for pre-ART loss-to-care. 
There was a considerable difference between the median waiting times for those pre-ART 
PLHIV who initiated ART, almost three months, versus 5 days of those who were lost to 
care. Ultimately the majority of pre-ART PLHIV lost to care only remained in care long 
enough to get their CD4 count results before being lost to the system. What was also 
interesting to find was that when waiting time was analysed per ART preparation step, 
the PLHIV who were lost to care had shorter waiting times at previous steps than those 
PLHIV who ultimately initiated ART.  
As the majority of pre-ART PLHIV who were lost to care had baseline CD4 counts less 
than 50 cells/uL, this trend was most likely due to these PLHIV being fast-tracked 
through the system. What is important to note is that this did not appear to improve the 
outcome for these PLHIV as they were still lost to care at one of the next steps. This was 
one of the reasons that Kaplan-Meier plots were not used to demonstrate the survival 
curve and time to event, as they did not reflect the true situation with regard to overall 
waiting time and its effect on loss-to-care. 
The Free State study looked specifically at waiting time for ART as one of the factors 
associated with pre-ART mortality and loss-to-care, but calculated the competing risks 
rather than Kaplan Meier survival estimates, as the Kaplan Meier estimates potentially 
gave misleading impression of pre-ART mortality. 
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According to the authors of the Free State study, so far only three other studies in 
resource-limited settings have assessed the waiting time for ART, with one of them being 
a study done previously at Sinikithemba. (28)  
This is quite surprising considering that this study also found that there was a strong 
relationship between waiting time for ART and the ART preparation system, amongst 
other health system factors. At Sinikithemba, changes made to the health system for 
reasons other than affecting the waiting time between steps were also shown to affect 
waiting time at. One such example was the increase in the time between baseline CD4 
count and the psychosocial assessment visit when Sinikithemba started using provincial 
laboratories for CD4 testing in January 2007.  
Up to January 2007, the time between CD4 count testing and the psychosocial assessment 
step was equivalent to the turn-around time for CD4 results from the private laboratory of 
6 days. When the provincial laboratory was used the waiting time increased to a median 
of 22 days, which was equivalent to the CD4 turn-around time of three weeks at the 
provincial laboratory. 
What is important to acknowledge is that although the time to ART initiation is “strongly 
associated with clinic-level factors”, health system changes do not necessarily have the 
desired impact on reducing ART preparation waiting time (28). This was clearly 
demonstrated by the comparison of the Batch ART Preparation System and the Daily 
ART Preparation System.  
This change in ART preparation system was specifically implemented in an effort to 
reduce the waiting lists and ultimately the waiting time for ART-eligible PLHIV at the 
psychosocial assessment step. The psychosocial assessment step had the greatest risk of 




However comparison of the two systems showed that despite the waiting time for the 
psychosocial assessment step being drastically reduced from a median of 31 days to 4 
days, the overall waiting time for ART actually increased from 37 days to 47 days and 
there was no significant difference in the proportion of PLHIV lost to care between the 
two different ART preparation steps. 
What was found was that although waiting time was reduced, the number of PLHIV that 
could be prepared for ART by the clinical staff did not change and therefore this 
bottleneck just ended up pushing back the waiting time to the next ART preparation step, 
which increased, from a median of 7 days to a median of 26 days. 
This finding highlights the interplay between the demand for ART and capacity of the 
clinic to supply ART. Improving the flow of pre-ART preparation PLHIV through the 
clinic and decreasing the waiting time for ART will not have the desired effect unless the 
health system has the capacity to initiate and absorb the increased number of PLHIV on 
ART. Limited resources and capacity will always result in increased waiting times and 
patient attrition as patient loads increase (28). 
One final result that was significant was that when waiting times between ART 
preparation steps was compared per enrolment month across the whole study period, only 
the waiting time between the psychosocial assessment and first ART literacy session was 
significantly associated with pre-ART loss-to-care. 
Despite health management decisions having an effect on waiting times between ART 
preparation steps and there being an associated risk of pre-ART loss-to-care for each 
ART preparation step, the greatest risk of pre-ART loss-to-care remained at the 
psychosocial assessment step even when the waiting time was drastically reduced from 
more than a month to less than a week.  
This again indicates that there are other factors associated with pre-ART loss-to-care, 
which are beyond the scope of this study and the available data. 
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5.3  LIMITATIONS AND CONFOUNDING 
“A disregard for the social and cultural context of adherence or the imposition of 
adherence models which are inconsistent with local values and practises is likely to 
produce irrelevant and ineffective interventions” (33) 
The greatest limitation of this study is that as a retrospective study only certain data 
elements were available for analysis. Whilst important information has been presented 
from this retrospective review, these findings are limited by the data available and 
ultimately can only reflect on pre-ART loss-to-care from the perspective of the health 
systems. What is critically missing is the perspective of the ART-eligible PLHIV 
themselves and the social, economical and cultural context they bring to the system, 
which could only be assessed in a prospective study with a qualitative component. 
This is most clearly seen in the fact that despite changes to the associated exposure 
variables such as waiting time and baseline CD4 count, and logistic regression 
controlling for confounding between these variables, the greatest risk of pre-ART loss-to-
care remained at the psychosocial assessment step. This indicates that there are other 
variables associated with pre-ART loss-to-care that are beyond the scope of this study. 
Other studies have highlighted potential confounders such as distance and accessibility to 
the clinic, employment obstacles and maybe most pertinent to this study, financial 
barriers to care. Another possible reason for the persistent loss-to-care at the psychosocial 
assessment step is that this is the step at which PLHIV find out they are eligible for ART, 
which in some cases could be only six days after finding out their HIV status. For some 
PLHIV, this may just be a little too much to handle all in one week. 
Without information from PLHIV themselves on their reasons for remaining in care or no 
longer accessing care, the conclusions drawn from this study are limited and due to the 
unknown affects of factors such as the clinic-fee cannot be generalised to other sites. 
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In addition to this, the lack of information on pre-ART loss-to-care mortality and silent 
transfers
13
, further limit the findings and conclusions that can be drawn both about the 
causality of pre-ART loss-to-care. Questions of whether pre-ART PLHIV are lost to care 
due to pre-ART mortality or whether pre-ART mortality is caused by pre-ART loss-to-
care cannot be answered.  
Even the high proportion of PLHIV lost to care can be questioned as it is not possible to 
define how many of these PLHIV are truly lost to care or are rather just lost from 
Sinikithemba due to transfer care elsewhere (12).  
Although delay in ART initiation was analysed at the third ART literacy step, this 
analysis could not be taken further as data on clinical or psychosocial delays between the 
other ART preparation steps were not available. This limits the generalisability of this 
finding to the other ART preparation steps and raises questions of confounding despite 
this variable remaining highly significant after controlling for the other associated 
variable describe in this study.  
This is especially so considering that this variable was no long significantly associated 
with pre-ART loss-to-care in the smaller subset of PLHIV who were prepared for ART 
after January 2007. Whilst this may be due to pre-ART PLHIV having better outcomes if 
they have reduced waiting time to their clinical consultations, this cannot be tested and 
confirmed without additional data.  
Even the conclusions drawn from analysing the two separate ART preparation systems 
are limited as the total number of PLHIV between the two systems were so different, 
(3976 and 1484) and only one year of the Daily ART Preparation System was compared 
to two-and-a-half years of the Batch ART Preparation System. The differences between 
the two systems could also have been confounded by the six months during which the 
Batch system was being phased out whilst the Daily System was being implemented.  
                                                 
13
 Silent Transfers refers to PLHIV who transfer their healthcare to another facility without informing the 
initial health facility where they were accessing care of this transfer out. 
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6 CHAPTER VI: RECOMMENDATIONS AND CONCLUSIONS 
 
6.1 INTRODUCTION 
This chapter presents conclusions based on the findings and discussion of each important 
issue explored in the study and highlights the main implications of these findings, with 
recommendations for the future. 
6.2 CONCLUSIONS 
The main purpose of this study was to quantify and describe loss-to-care in people living 
with HIV (PLHIV) that are eligible for antiretroviral therapy (ART) and analyse the 
available demographic, clinical and health system related factors that affect pre-ART 
loss-to-care.  With the emphasis of HIV programmes and research focused on the rapid 
scale-up of ART for the last few years, the pre-ART outcomes have not been adequately 
documented. The large sample size and three-and-a-half year follow up period provided a 
large dataset to demonstrate that pre-ART loss-to-care of ART-eligible PLHIV is a 
significant problem that needs to be further investigated.  
The low median CD4 counts of pre-ART PLHIV indicates that the majority of ART-
eligible PLHIV are entering ART preparation care at the end stages of acquired 
immunodeficiency syndrome (AIDS) disease rather than the threshold for ART initiation 
and this is affecting on the retention of pre-ART PLHIV in HIV care. The association of 
male gender with pre-ART loss-to-care, adds to the growing body of evidence that HIV 
health care systems are not set up to attract and retain males in care. 
The high prevalence of HIV in KwaZulu Natal has resulted in the numbers of ART-
eligible PLHIV exceeding the capacity of the health care system to meet the demand for 
ART. This has resulted in waiting lists and delays for ART-eligible PLHIV, which 
further impact pre-ART loss-to-care. 
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There is little evidence available to support the adopted process of ART preparation, yet 
in the absence of a better system, the ART preparation process has become a means of 
rationing the limited resources available for ART initiation rather than a programme 
focused on efficiently attracting and retaining HIV PLHIV into care at early stages of 
HIV infection.   
The ART preparation steps associated with the longest waiting time and highest risk of 
pre-ART loss-to-care occurs at the point of accessing clinical care and reflects the rate-
limiting effect of clinical capacity. Efforts to reduce the pre-ART waiting time at these 
steps did not influence overall waiting time for ART initiation and retention in care, as 
the clinical capacity to manage increased numbers of PLHIV did not improve.  
The public health benefits of retaining PLHIV in HIV care necessitates that further 
research is conducted to report on the attrition points and predictors of pre-ART loss-to-
care and provide evidence for the changes that need to be made to improve this situation 
(2). 
6.3 RECOMMENDATIONS: PROGRAMME LEVEL  
The highest mortality at ART sites with limited resources is found in those PLHIV who 
present late for treatment; improved access to care and treatment means improved disease 
stage and reduced mortality. Focusing retention strategies at the pre-ART stage and not 
just the ART initiation stage will have an impact on overall programme outcomes:  
1. Targeted follow up of ART-eligible PLHIV at the ART preparation steps 
associated with the greatest risk of pre-ART loss-to-care. These strategies can 
focus initially on pre-ART loss-to-care ascertainment and as information and 
understanding of pre-ART retention improves, can inform new retention 
strategies.  
2. Targeted recruitment and follow up of male PLHIV 
3. Development of monitoring and evaluation indicators for measuring the outcomes 
of pre-ART retention strategies. 
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4. Development of pre-ART Wellness programme in order to encourage PLHIV to 
enter and remain in care prior to being ART eligible and ultimately improve the 
clinical outcomes of PLHIV prepared and initiated on ART. 
5. Use emerging research findings to modify the ART preparation process in order 
to reduce the number of preparation visits required, decentralize the ART 
preparation process, address competing risks for pre-ART loss-to-care and 
increase the numbers of PLHIV initiated and maintained on ART. 
6.4 RECOMMENDATIONS: FURTHER STUDY 
The outcome of pre-ART programmes, including death and loss-to-care are not 
adequately documented as most literature is focused on the outcomes of ART 
programmes. It is imperative that research, specifically focused on this stage of HIV care 
and treatment is conducted and provides evidence for developing strategies to increase 
access to ART without over-saturating the clinic: 
1. Systematic analysis of the flow of PLHIV through all components of the HIV 
programme needs to be conducted to evaluate the effectiveness of HIV care and 
treatment strategies and identify bottlenecks and unnecessary delays. 
2. Prospective qualitative methods need to be used to follow up pre-ART PLHIV 
both lost to care and retained in care so that associations can be explained. 
3. Longitudinal operational research evaluating the effects of changes to the ART 
preparation process and the association between clinical consultations and 
retention in care. 
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Table 8.1: List of Key Data Elements extracted from TrakCare, 01 August 2009 
Gender 
Enrolment Age 
Date of First CD4 Count  
Result of First CD4 Count  
Date of Baseline CD4 count  
Result of Baseline CD4 count 
Date of First ART Preparation Visit 
Category of First ART Preparation Visit 
Date of ART Preparation Visit 
Category of ART Preparation Visit 
Date of Last ART Preparation Visit 
Category of Last ART Preparation Visit 
ART Start Date 








 Table 8.2 List of Variables generated for data analysis 
Gender Categorical Male (1); Female (2) 
Enrolment Age Continuous Years 
Enrolment Age Bands Ordinal 15-29 yr (1); 30-39 (2); 40-49 (3); 50+ (4) 
Enrolment Group Ordinal Months (1-42): July 2004-December 2007 
ART Preparation Programme Categorical Batch System:(0); Daily System:(1) 
First Visit Date Continuous Date 
First Visit Category Categorical HIV Test; CD4 Test; PSA; ART1; ART 2; 
ART 3; ART Start; Non-ART prep Visit 
ART Eligibility CD4 Date Continuous Date 
ART Eligibility CD4 Result Continuous Number 
ART Eligibility CD4 Bands Categorical 0-50 (1); 51-100 (2); 101-150 (3); 151-200 (4) 
Pre-ART Eligibility Care Categorical Accessed Care when CD4<=200 (0); Accessed 
Care when CD4>200 (1) 
Pre-ART Eligibility Time in Care Continuous Days 
Pre-ART Eligibility CD4 Date Continuous Date 
Pre-ART Eligibility CD4 Result Continuous CD4>200 Result 
Pre-ART Eligibility CD4 Monitoring Categorical No CD4>200 Monitoring (0); CD4>200 
Monitoring (1) 
Pre-ART Eligibility CD4 Monitoring Time Continuous Days 
ART preparation Psychosocial Assessment 
Visit 
Continuous Date 
ART preparation ART Literacy 1 Visit Continuous Date 
ART preparation ART Literacy 2 Visit Continuous Date 
ART preparation Third ART literacy Visit Continuous Date 
Last Visit Date Continuous Date 
Last Visit Category Categorical HIV Test; CD4 Test; PSA; ART1; ART 2; 
ART 3; ART Start; Non-ART prep Visit 
ART Start Date Continuous Date 
Lost To Care Categorical Visit date less than 6 months before  
ART Eligibility CD4 to Psychosocial 
Assessment Time 
Continuous Days 
Psychosocial Assessment to ART Literacy 1 
Time 
Continuous Days 
ART Literacy 1 to ART Literacy 2 Time Continuous Days 
ART Literacy 2 to Third ART literacy Time Continuous Days 
Third ART literacy to ART Start Time Continuous Days 
ART Start Delay Time Continuous Days 
 
